Table 3.
Examples of radiopharmaceuticals currently in clinical trials in cancer patients
| Nuclide | Therapeutic (Trade Name/Scientific Name) |
Target | Tumour Type | Industrial Sponsor |
|---|---|---|---|---|
| Neuroendocrine tumours | ||||
| 177Lu | Satoreotide (OPS201, JR11) | STTR2 | NENs | Ipsen/Satosea |
| 177Lu | Edotreotide (DOTATOC, ITM-11) | SSTR2 | NENs | ITM |
| 177Lu | Lutathera (DOTA-TATE) | SSTR2 | GEP-NETs, SCLC, GBM | Novartis (Advanced Accelerator Applications) |
| 177Lu | DOTA-LM3 | SSTR2 | NENs | (42) |
| 212Pb | AlphaMedix (DOTAM-TATE) | SSTR2 | NENs | Radiomedix |
| 225Ac | DOTATOC | SSTR2 | NENs | (93) |
| 225Ac | DOTATATE | SSTR2 | NENs | (94) |
| 225Ac | DOTA-LM3 | SSTR2 | NENs | (43) |
| Prostate Cancer | ||||
| 225Ac | RYZ101 | SSTR2 | GEP-NETs | Rayzebio |
| 177Lu | TLX591 (Rosopatamab) | PSMA | mCRPC | Telix Pharmaceuticals |
| 177Lu | PNT2002 (PSMA I&T) | PSMA | mCRPC | POINT Biopharma Lantheus |
| 177Lu | PSMA I&T | PSMA | mCRPC | Curium US LLC |
| 177Lu | PSMA-617 | PSMA | mCRPC, mHSPC | Novartis |
| Other Cancers | ||||
| 225Ac | Actimab-A (Lintuzumab) | CD33 | AML | Actinium Pharmaceuticals |
| 225Ac | FPI-1434 | IGF-1R | Solid tumours | Fusion Pharmaceuticals |
| 225Ac | FPI-1966 | FGFR3 | Solid tumours | Fusion Pharmaceuticals |
| 131I | TLX101 (Iodophenylalanine) | LAT-1 | GBM | Telix Pharmaceuticals |
| 131I | HER2-VHH | HER2 | breast | VU Brussels, Belgium |
| 131I | Iomab-B (Apamistamab) | CD45 | AML | Actinium Pharmaceuticals |
| 131I, 177Lu | Omburtamab | B7-H3 | NB, MB | Y-mabs Therapeutics |
| 177Lu | TLX250 (Girentuximab) | CA9 | ccRCC | Telix Pharmaceuticals |
| 177Lu | Betalutin (Lilotomab) | CD37 | NHL | Nordic Nanovector |
| 177Lu | FAP-2286 | FAP | Solid tumours | Novartis |
| 177Lu | PNT6555 | FAP | Solid tumours | POINT Biopharma |
| 177Lu | Hurlutin | αvβ3 | Breast | Advanced Imaging Projects |
| 177Lu | NeoB | GRPR | Solid tumours | Advanced Accelerator Applications |
| 177Lu | DOTA-FAPI | FAP | various | Xiamen University, China |
| 177Lu | EB-FAPI | FAP | various | Peking Union Medical College Hospital and Xiamen University, China |
| 177Lu | PP-F11N | CCK-2R | thyroid | University Hospitals Basel, Freiburg, Zurich, Bern and PSI Villigen, Switzerland, Germany |
STTR2, somatostatin receptor 2; PSMA, prostate specific membrane antigen; FAP, fibroblast activation protein; NENs, neuroendocrine tumours; GEP-NETs, gastroenteropancreatic neuroendocrine tumours; FGFR3, fibroblast growth factor receptor 3; GRPR, gastrin-releasing peptide receptor; SCLC, small cell lung carcinoma; GBM, glioblastoma; AML, acute myeloid leukaemia; mCRPC, metastatic castrate resistant prostate cancer; mHSPC, metastatic hormone sensitive prostate cancer; NHL, non-Hodgkins lymphoma; NB, neuroblastoma; MB, medulloblastoma; ccRCC, clear cell renal cell carcinoma. HER2 human epidermal growth factor receptor 2; CCK-2R, Cholecystokinin-2 receptor